Nutritional deficiency and genetic errors that impair the transport, absorption, and utilization of vitamin B (B) lead to hematological and neurological manifestations. The cblC disease (cobalamin complementation type C) is an autosomal recessive disorder caused by mutations and epi-mutations in the gene and the most common inborn error of B metabolism. Pathogenic mutations in disrupt enzymatic processing of B, an indispensable step before micronutrient utilization by the two B-dependent enzymes methionine synthase (MS) and methylmalonyl-CoA mutase (MUT). As a result, patients with cblC disease exhibit plasma elevation of homocysteine (Hcy, substrate of MS) and methylmalonic acid (MMA, degradation product of methylmalonyl-CoA, substrate of MUT). The cblC disorder manifests early in childhood or in late adulthood with heterogeneous multi-organ involvement. This review covers current knowledge on the cblC disease, structure-function relationships of the MMACHC protein, the genotypic and phenotypic spectra in humans, experimental disease models, and promising therapies.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9464900 | PMC |
http://dx.doi.org/10.1016/j.isci.2022.104981 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!